These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9409653)

  • 41. Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain.
    Wally J; Kica G; Zhang Y; Ericsson T; Connors LH; Benson MD; Liepnieks JJ; Murray J; Skinner M; Comenzo RL
    Biochim Biophys Acta; 1999 May; 1454(1):49-56. PubMed ID: 10354514
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Kidney and liver involvement in monoclonal light chain disorders.
    Pozzi C; Locatelli F
    Semin Nephrol; 2002 Jul; 22(4):319-30. PubMed ID: 12118397
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Abnormal immunoglobulin synthesis in monoclonal immunoglobulin light chain and light and heavy chain deposition disease.
    Buxbaum JN
    Amyloid; 2001 Jun; 8(2):84-93. PubMed ID: 11409038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis
    Renz M; Torres R; Dolan PJ; Tam SJ; Tapia JR; Li L; Salmans JR; Barbour RM; Shughrue PJ; Nijjar T; Schenk D; Kinney GG; Zago W
    Amyloid; 2016 Sep; 23(3):168-177. PubMed ID: 27494229
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical and immunochemical study of amyloid in liver affected by systemic Alambda amyloidosis with antibodies against three different regions of immunoglobulin lambda light chain.
    Kiyama M; Hoshii Y; Cui D; Kawano H; Kanda T; Ishihara T
    Pathol Int; 2007 Jun; 57(6):343-50. PubMed ID: 17539965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary amyloidosis associated with a novel heavy-chain fragment (AH amyloidosis).
    Solomon A; Weiss DT; Murphy C
    Am J Hematol; 1994 Feb; 45(2):171-6. PubMed ID: 8141123
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease.
    Déret S; Chomilier J; Huang DB; Preud'homme JL; Stevens FJ; Aucouturier P
    Protein Eng; 1997 Oct; 10(10):1191-7. PubMed ID: 9488143
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary local orbital amyloidosis: biochemical identification of the immunoglobulin light chain kappaIII subtype in a small formalin fixed, paraffin wax embedded tissue sample.
    Kaplan B; Martin BM; Cohen HI; Manaster J; Kassif Y; Rehany U; Livneh A
    J Clin Pathol; 2005 May; 58(5):539-42. PubMed ID: 15858128
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases.
    Turbat-Herrera EA; Isaac J; Sanders PW; Truong LD; Herrera GA
    Mod Pathol; 1997 May; 10(5):485-95. PubMed ID: 9160315
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogold quantitation of immunoglobulin light chains in renal amyloidosis and kappa light chain nephropathy.
    Silver MM; Hearn SA; Walton JC; Lines LA; Walley VM
    Am J Pathol; 1990 May; 136(5):997-1007. PubMed ID: 1693473
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pulmonary light chain deposition disease: report of five cases and review of the literature.
    Bhargava P; Rushin JM; Rusnock EJ; Hefter LG; Franks TJ; Sabnis SG; Travis WD
    Am J Surg Pathol; 2007 Feb; 31(2):267-76. PubMed ID: 17255772
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Brain-restricted amyloidoma of immunoglobulin lambda-light chain origin clinically resembling multiple sclerosis.
    Linke RP; Gerhard L; Lottspeich F
    Biol Chem Hoppe Seyler; 1992 Dec; 373(12):1201-9. PubMed ID: 1292505
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Potential role of apolipoprotein-E in fibrillogenesis.
    Gallo G; Wisniewski T; Choi-Miura NH; Ghiso J; Frangione B
    Am J Pathol; 1994 Sep; 145(3):526-30. PubMed ID: 8080036
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis.
    Enqvist S; Sletten K; Stevens FJ; Hellman U; Westermark P
    PLoS One; 2007 Oct; 2(10):e981. PubMed ID: 17912358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunohistochemical distinction between amyloidosis and fibrillar glomerulopathy.
    Casanova S; Donini U; Zucchelli P; Mazzucco G; Monga G; Linke RP
    Am J Clin Pathol; 1992 Jun; 97(6):787-95. PubMed ID: 1595598
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amyloidosis of the breast.
    Röcken C; Kronsbein H; Sletten K; Roessner A; Bässler R
    Virchows Arch; 2002 May; 440(5):527-35. PubMed ID: 12021928
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Partial amino acid sequence of an amyloid fibril protein from unusual cutaneous cystic lesions in myeloma-associated amyloidosis.
    Akiyama T; Seishima M; Nojiri M; Satoh M; Ichiki Y; Kitajima Y
    Eur J Dermatol; 1999 Dec; 9(8):624-8. PubMed ID: 10586130
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Isolation and characterization of a kappa amyloid fibril protein.
    Gertz MA; Skinner M; Cohen AS; Connors LH; Kyle RA
    Scand J Immunol; 1985 Sep; 22(3):245-50. PubMed ID: 2864740
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal granular monoclonal light chain deposits: morphological aspects in 11 cases.
    Noel LH; Droz D; Ganeval D; Grunfeld JP
    Clin Nephrol; 1984 May; 21(5):263-9. PubMed ID: 6428790
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Classification of cardiac amyloidosis: an immunohistochemical analysis].
    Li L; Duan XJ; Sun Y; Lu Y; Xu HY; Wang QZ; Wang HY
    Zhonghua Bing Li Xue Za Zhi; 2018 Feb; 47(2):105-109. PubMed ID: 29429161
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.